293 related articles for article (PubMed ID: 27713259)
1. Deregulation of Interferon Signaling in Malignant Cells.
Katsoulidis E; Kaur S; Platanias LC
Pharmaceuticals (Basel); 2010 Feb; 3(2):406-418. PubMed ID: 27713259
[TBL] [Abstract][Full Text] [Related]
2. Type I interferons in the pathogenesis and treatment of canine diseases.
Klotz D; Baumgärtner W; Gerhauser I
Vet Immunol Immunopathol; 2017 Sep; 191():80-93. PubMed ID: 28895871
[TBL] [Abstract][Full Text] [Related]
3. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative effects of interferons on human melanoma cells in the human tumor colony-forming assay.
Schiller JH; Willson JK; Bittner G; Wolberg WH; Hawkins MJ; Borden EC
J Interferon Res; 1986 Dec; 6(6):615-25. PubMed ID: 2437222
[TBL] [Abstract][Full Text] [Related]
5. Interferon: cellular executioner or white knight?
Maher SG; Romero-Weaver AL; Scarzello AJ; Gamero AM
Curr Med Chem; 2007; 14(12):1279-89. PubMed ID: 17504213
[TBL] [Abstract][Full Text] [Related]
6. Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes.
Fish EN; Platanias LC
Mol Cancer Res; 2014 Dec; 12(12):1691-703. PubMed ID: 25217450
[TBL] [Abstract][Full Text] [Related]
7. Importance of Type I and III Interferons at Respiratory and Intestinal Barrier Surfaces.
Stanifer ML; Guo C; Doldan P; Boulant S
Front Immunol; 2020; 11():608645. PubMed ID: 33362795
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of type I interferon signaling in normal and malignant cells.
Li Y; Srivastava KK; Platanias LC
Arch Immunol Ther Exp (Warsz); 2004; 52(3):156-63. PubMed ID: 15247882
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo.
Sayers TJ; Wiltrout TA; McCormick K; Husted C; Wiltrout RH
Cancer Res; 1990 Sep; 50(17):5414-20. PubMed ID: 2117482
[TBL] [Abstract][Full Text] [Related]
10. Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors.
Wagner TC; Velichko S; Chesney SK; Biroc S; Harde D; Vogel D; Croze E
Int J Cancer; 2004 Aug; 111(1):32-42. PubMed ID: 15185340
[TBL] [Abstract][Full Text] [Related]
11. Type III and Not Type I Interferons Efficiently Prevent the Spread of Rotavirus in Human Intestinal Epithelial Cells.
Doldan P; Dai J; Metz-Zumaran C; Patton JT; Stanifer ML; Boulant S
J Virol; 2022 Sep; 96(17):e0070622. PubMed ID: 36000839
[TBL] [Abstract][Full Text] [Related]
12. Somnogenic effects of rabbit and recombinant human interferons in rabbits.
Kimura M; Majde JA; Toth LA; Opp MR; Krueger JM
Am J Physiol; 1994 Jul; 267(1 Pt 2):R53-61. PubMed ID: 7519411
[TBL] [Abstract][Full Text] [Related]
13. Differential Regulation of Type I and Type III Interferon Signaling.
Stanifer ML; Pervolaraki K; Boulant S
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901970
[TBL] [Abstract][Full Text] [Related]
14. Effects of scheduling and ascites-associated macrophages on combined antiproliferative activity of alpha-2b interferon and gamma-interferon in a clonogenic assay.
Higashihara J; Saito T; Berens ME; Welander CE
Cancer Chemother Pharmacol; 1988; 22(3):215-22. PubMed ID: 3136942
[TBL] [Abstract][Full Text] [Related]
15. Interferons, interferon-like cytokines, and their receptors.
Pestka S; Krause CD; Walter MR
Immunol Rev; 2004 Dec; 202():8-32. PubMed ID: 15546383
[TBL] [Abstract][Full Text] [Related]
16. Herpesviruses and the Type III Interferon System.
Yin Y; Favoreel HW
Virol Sin; 2021 Aug; 36(4):577-587. PubMed ID: 33400088
[TBL] [Abstract][Full Text] [Related]
17. Type I and Type III Interferons Display Different Dependency on Mitogen-Activated Protein Kinases to Mount an Antiviral State in the Human Gut.
Pervolaraki K; Stanifer ML; Münchau S; Renn LA; Albrecht D; Kurzhals S; Senís E; Grimm D; Schröder-Braunstein J; Rabin RL; Boulant S
Front Immunol; 2017; 8():459. PubMed ID: 28484457
[TBL] [Abstract][Full Text] [Related]
18. Bioconjugation strategies and clinical implications of Interferon-bioconjugates.
Hauptstein N; Meinel L; Lühmann T
Eur J Pharm Biopharm; 2022 Mar; 172():157-167. PubMed ID: 35149191
[TBL] [Abstract][Full Text] [Related]
19. [Action of type III IFNs and their roles in immune responses].
Domagalski K; Tretyn A; Pawłowska M; Szczepanek J; Halota W
Postepy Hig Med Dosw (Online); 2010 Oct; 64():522-33. PubMed ID: 21109705
[TBL] [Abstract][Full Text] [Related]
20. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo.
Ank N; West H; Bartholdy C; Eriksson K; Thomsen AR; Paludan SR
J Virol; 2006 May; 80(9):4501-9. PubMed ID: 16611910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
